LIVIVO - Search results -

Search results

Result 1 - 10 of total 64

Search options

Article: Ten-Year Risk for Developing Cardiovascular Disease Among Older Adults and Elderly in India: A Secondary Analysis of Wave-1 of Longitudinal Aging Study in India.

Loganathan, Vignesh / Subramanian, Muthathal / Sekhar Kar, Sitanshu

2023 Volume 15, Issue 10, Page(s) e46772

Abstract: Background Cardiovascular disease (CVD) risk stratification is recommended by the World Health Organization (WHO) for effective CVD management in primary healthcare settings. Using the 2019 updated WHO CVD risk charts, we estimated the 10-year risk for ... ...

Abstract	Background Cardiovascular disease (CVD) risk stratification is recommended by the World Health Organization (WHO) for effective CVD management in primary healthcare settings. Using the 2019 updated WHO CVD risk charts, we estimated the 10-year risk for developing fatal and non-fatal CVD among participants of the Longitudinal Aging Study in India (LASI). Methods We conducted secondary data analysis using the Wave-1 dataset of LASI. Analysis was performed in Stata software (version 14.1; StataCorp LLC, College Station, Texas) after applying sample weights. Ten-year CVD risk was estimated using a non-laboratory-based CVD risk chart. Logistic regression analysis was performed to determine the association between socio-demographic characteristics and 10% or more 10-year CVD risk. Results The weighted prevalence of 10% or more 10-year CVD risk was 24.70% (95% CI: 23.94%-25.47%). Participants who were currently working, living alone, and widowed had 3.63, 1.42, and 1.59 times increased odds of having a high 10-year CVD risk, respectively, after adjusting for other variables. Conclusion About a quarter of older adults and the elderly population in India have a 10-year risk for a fatal or non-fatal cardiovascular event of 10% or more, as estimated using a non-laboratory based chart.
Language	English
Publishing date	2023-10-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	2747273-5
ISSN	2168-8184
ISSN	2168-8184
DOI	10.7759/cureus.46772
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus.

Joshi, Shashank / Jayanth, Vathsala / Loganathan, Subramanian / Sambandamurthy, Vasan K / Athalye, Sandeep N

Drugs

2023 Volume 83, Issue 13, Page(s) 1161–1178

Abstract: Insulin therapy is indispensable for achieving glycemic control in all patients with type 1 diabetes mellitus and many patients with type 2 diabetes mellitus. Insulin injections are associated with negative connotations in patients owing to ... ...

Abstract	Insulin therapy is indispensable for achieving glycemic control in all patients with type 1 diabetes mellitus and many patients with type 2 diabetes mellitus. Insulin injections are associated with negative connotations in patients owing to administration discomfort and adverse effects such as hypoglycemia and weight gain. Insulin administered orally can overcome these limitations by providing a convenient and effective mode of delivery with a potentially lower risk of hypoglycemia. Oral insulin mimics the physiologic process of insulin secretion, absorption into the portal circulation, and subsequent peripheral delivery, unlike the subcutaneous route that results in peripheral hyperinsulinemia. Insulin tregopil (IN-105), a new generation human recombinant insulin, methoxy (polyethylene glycol) hexanoyl human recombinant insulin, is developed by Biocon as an ultra-fast onset short-acting oral insulin analog. This recombinant oral insulin is a single short-chain amphiphilic oligomer modified with the covalent attachment of methoxy-triethylene-glycol-propionyl moiety at Lys-β
MeSH term(s)	Humans ; Blood Glucose ; Diabetes Mellitus, Type 1/drug therapy ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemia/drug therapy ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Insulin/analogs & derivatives ; Insulin/therapeutic use ; Insulin Aspart/therapeutic use ; Recombinant Proteins/therapeutic use
Chemical Substances	Blood Glucose ; Hypoglycemic Agents ; Insulin ; Insulin Aspart (D933668QVX) ; Recombinant Proteins
Language	English
Publishing date	2023-08-14
Publishing country	New Zealand
Document type	Review ; Journal Article
ZDB-ID	120316-2
ISSN	1179-1950 ; 0012-6667
ISSN (online)	1179-1950
ISSN	0012-6667
DOI	10.1007/s40265-023-01925-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 762: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Seasonality of macrobenthic assemblages and the biotic environmental quality of the largest monsoonal estuary along the west coast of India.

Rethinam Subramanian, Pandiya Rajan / Retnamma, Jyothibabu / Nagarathinam, Arunpandi / Loganathan, Jagadeesan / Singaram, Parthasarathi / Chandrababu, Vishnu

Environmental science and pollution research international

2021 Volume 28, Issue 28, Page(s) 37262–37278

Abstract: This study deals with the macrobenthic assemblages and the biotic environmental quality of Kochi backwaters (KBW), India. Due to the heavy river discharge, extensive limnetic and turbid conditions prevailed in the KBW during the southwest monsoon (June ... ...

Abstract	This study deals with the macrobenthic assemblages and the biotic environmental quality of Kochi backwaters (KBW), India. Due to the heavy river discharge, extensive limnetic and turbid conditions prevailed in the KBW during the southwest monsoon (June to September). This exerted a profound adverse effect on the abundance, richness, and diversity of macrobenthic assemblages. Overall, mesohaline conditions with a clayey sand bottom substratum favored the high macrofaunal abundance during the southwest and northeast monsoon seasons. But mesohaline condition and sandy silt bottom were found to support high macrofaunal abundance in the KBW during the pre-monsoon season. Polychaete dominated the macrobenthic community, regardless of seasons. Capitella capitata, Heteromastus similis, Paraheteromastus sp., Prionospio cirrobranchiata, Minuspio cirrifera, Pagurapseudopsis kochindica, P. gymnophobia, Ctenapseudes indiana, C.chilkensis, Tanais sp., Villorita cyprinoides, Grandidierella sp., Ampelisca sp., and Littorina sp. were the dominant ones observed during the study. The sediment organic carbon, in general, showed a positive correlation with polychaete abundance during all three seasons. The ecological status of KBW during all three seasons was assessed as per BO2A index, which ranged from 0.05 to 0.18, suggesting a healthy to a moderately polluted bottom environmental condition.
Language	English
Publishing date	2021-03-13
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1178791-0
ISSN	1614-7499 ; 0944-1344
ISSN (online)	1614-7499
ISSN	0944-1344
DOI	10.1007/s11356-021-13144-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 5915: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Pharmacoinformatic approach to identify potential phytochemicals against SARS-CoV-2 spike receptor-binding domain in native and variants of concern.

Chinnadurai, Raj Kumar / Ponne, Saravanaraman / Chitra, Loganathan / Kumar, Rajender / Thayumanavan, Palvannan / Subramanian, Balanehru

Molecular diversity

2022 Volume 27, Issue 6, Page(s) 2741–2766

Abstract: Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) pathogenesis is initiated by the binding of SARS-CoV-2 spike (S) protein with the angiotensin-converting enzyme 2 receptor (ACE2R) on the host cell surface. The receptor-binding domain ( ...

Abstract	Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) pathogenesis is initiated by the binding of SARS-CoV-2 spike (S) protein with the angiotensin-converting enzyme 2 receptor (ACE2R) on the host cell surface. The receptor-binding domain (RBD) of the S protein mediates the binding and is more prone to mutations resulting in the generation of different variants. Recently, molecules with the potential to inhibit the interaction of S protein with ACE2R have been of interest due to their therapeutic value. In this context, the present work was performed to identify potential RBD binders from the Indian medicinal plant's phytochemical database through virtual screening, molecular docking, and molecular dynamic simulation. Briefly, 1578 compounds filtered from 9596 phytochemicals were chosen for screening against the RBD of the native SARS-CoV-2 S protein. Based on the binding energy, the top 30 compounds were selected and re-docked individually against the native and five variants of concern (VOCs: alpha, beta, gamma, delta, and omicron) of SARS-CoV-2. Four phytochemicals, namely withanolide F, serotobenine, orobanchol, and gibberellin A51, were found to be potential RBD binders in native and all SARS-CoV-2 VOCs. Among the four, withanolide F exhibited lower binding energy (- 10.84 to - 8.56 kcal/mol) and better ligand efficiency (- 0.3 to - 0.25) against all forms of RBD and hence was subjected to a 100 ns MD simulation which confirmed its stringent binding to the RBDs in native and VOCs. The study prioritizes withanolide F as a prospective COVID-19 (Coronavirus disease) therapeutic agent based on the observations. It warrants deeper investigations into the four promising leads for understanding their precise therapeutic value.
MeSH term(s)	Humans ; SARS-CoV-2 ; COVID-19 ; Molecular Docking Simulation ; Withanolides ; Protein Binding ; Molecular Dynamics Simulation
Chemical Substances	spike protein, SARS-CoV-2 ; Withanolides
Language	English
Publishing date	2022-12-22
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1376507-3
ISSN	1573-501X ; 1381-1991
ISSN (online)	1573-501X
ISSN	1381-1991
DOI	10.1007/s11030-022-10580-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4946: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evaluation of clinical practice guidelines (CPG) on the management of female chronic pelvic pain (CPP) using the AGREE II instrument.

Ghai, Vishalli / Subramanian, Venkatesh / Jan, Haider / Loganathan, Jemina / Doumouchtsis, Stergios K

International urogynecology journal

2021 Volume 32, Issue 11, Page(s) 2899–2912

Abstract: Introduction and hypothesis: Variations in guidelines may result in differences in treatments and potentially poorer health-related outcomes. We aimed to systematically review and evaluate the quality of national and international guidelines and create ... ...

Abstract	Introduction and hypothesis: Variations in guidelines may result in differences in treatments and potentially poorer health-related outcomes. We aimed to systematically review and evaluate the quality of national and international guidelines and create an inventory of CPG recommendations on CPP. Methods: We searched EMBASE and MEDLINE databases from inception till August 2020 as well as websites of professional organizations and societies. We selected national and international CPGs reporting on the diagnosis and management of female CPP. We included six CPGs. Five researchers independently assessed the quality of included guidelines using the AGREE II tool and extracted recommendations. Results: Two hundred thirty-two recommendations were recorded and grouped into six categories: diagnosis, medical treatment, surgical management, behavioural interventions, complementary/alternative therapies and education/research. Thirty-nine (17.11%) recommendations were comparable including: a comprehensive pain history, a multi-disciplinary approach, attributing muscular dysfunction as a cause of CPP and an assessment of quality of life. Two guidelines acknowledged sexual dysfunction associated with CPP and recommended treatment with pelvic floor exercises and behavioural interventions. All guidelines recommended surgical management; however, there was no consensus regarding adhesiolysis, bilateral salpingo-oophorectomy during hysterectomy, neurectomy and laparoscopic uterosacral nerve ablation. Half of recommendations (106, 46.49%) were unreferenced or made in absence of good-quality evidence or supported by expert opinion. Based on the AGREE II assessment, two guidelines were graded as high quality and recommended without modifications (EAU and RCOG). Guidelines performed poorly in the "Applicability", "Editorial Independence" and "Stakeholder Involvement" domains. Conclusion: Majority of guidelines were of moderate quality with significant variation in recommendations and quality of guideline development.
MeSH term(s)	Chronic Pain/etiology ; Chronic Pain/therapy ; Consensus ; Databases, Factual ; Female ; Humans ; Pelvic Pain/etiology ; Pelvic Pain/therapy ; Practice Guidelines as Topic ; Quality of Life
Language	English
Publishing date	2021-06-19
Publishing country	England
Document type	Journal Article ; Systematic Review
ZDB-ID	1050631-7
ISSN	1433-3023 ; 0937-3462
ISSN (online)	1433-3023
ISSN	0937-3462
DOI	10.1007/s00192-021-04848-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3070: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.

Loganathan, Subramanian / Athalye, Sandeep N / Joshi, Shashank R

Expert opinion on biological therapy

2020 Volume 20, Issue 9, Page(s) 1025–1031

Abstract: Introduction: The globally rampant SARS CoV-2 pandemic requires novel medical strategies to control the severity of disease and death due to complications. Of the 15-20% patients that develop pulmonary symptoms, a sub-set develops an acute respiratory ... ...

Abstract	Introduction: The globally rampant SARS CoV-2 pandemic requires novel medical strategies to control the severity of disease and death due to complications. Of the 15-20% patients that develop pulmonary symptoms, a sub-set develops an acute respiratory distress syndrome (ARDS) rapidly progressing into a critical condition. Marked elevation of cytokines/chemokines is observed with elevation of additional markers of inflammation, coagulation, and organ damage such as CRP, D-dimer, LDH, Ferritin and Troponin-I. This hyperinflammation leads to worsening of oxygen saturation due to pulmonary infiltration and exudation, organ damage, and dysfunction of coagulation pathway and may lead to multi-organ failure. Areas covered: The role of anti-inflammatory monoclonal antibodies such as Itolizumab, in cytokine storm. Expert opinion: Itolizumab, an
MeSH term(s)	Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antigens, CD/immunology ; Antigens, Differentiation, T-Lymphocyte/immunology ; Betacoronavirus ; COVID-19 ; Cell Differentiation/drug effects ; Cell Differentiation/physiology ; Cell Proliferation/drug effects ; Cell Proliferation/physiology ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Cytokines/antagonists & inhibitors ; Cytokines/immunology ; Humans ; Lymphocyte Activation/drug effects ; Lymphocyte Activation/physiology ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; SARS-CoV-2 ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antigens, CD ; Antigens, Differentiation, T-Lymphocyte ; CD6 antigen ; Cytokines ; itolizumab (XQQ2RHV14N)
Keywords	covid19
Language	English
Publishing date	2020-07-29
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2052501-1
ISSN	1744-7682 ; 1471-2598
ISSN (online)	1744-7682
ISSN	1471-2598
DOI	10.1080/14712598.2020.1798399
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6094: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.

Andersen, Grit / Singh, Gursharan / Murugesan, Sundara Moorthi Nainar / Gogineni, Rajesh / Sharma, Nirant / Panda, Jayanti / Marwah, Ashwani / Loganathan, Subramanian / Athalye, Sandeep N

Diabetes, obesity & metabolism

2023 Volume 25, Issue 6, Page(s) 1485–1494

Abstract: Aim: To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar Insulin N (Biocon's Insulin-N; Biocon Biologics Ltd., Bangalore, India) and US-licensed Humulin® N (Humulin-N; Eli Lilly and Company, Indianapolis, IN, ...

Abstract	Aim: To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar Insulin N (Biocon's Insulin-N; Biocon Biologics Ltd., Bangalore, India) and US-licensed Humulin® N (Humulin-N; Eli Lilly and Company, Indianapolis, IN, USA) in healthy subjects. Materials and methods: This was a phase-1, single-centre, double-blind, randomized, three-period, six-sequence, partially replicated, crossover, 24-h euglycaemic clamp study. Overall, 90 healthy subjects were randomized, of whom 85 completed the study. The subjects received either two single doses of Biocon's Insulin-N and a single dose of Humulin-N or two single doses of Humulin-N and a single dose of Biocon's Insulin-N subcutaneously at a dose of 0.4 IU/kg. The primary PK endpoints were the area under the insulin concentration-time curve from 0 to 24 h (AUC Results: Biocon's Insulin-N was found to be equivalent to Humulin-N for the primary PK (geometric 90% confidence interval for the least squares mean ratio: AUC Conclusion: PK and PD equivalence was shown between Biocon's Insulin-N and Humulin-N in healthy subjects, and both treatments were well tolerated and considered safe.
MeSH term(s)	Humans ; Insulin ; Insulin, Regular, Human ; Biosimilar Pharmaceuticals/therapeutic use ; Hypoglycemic Agents ; Healthy Volunteers ; India ; Insulin, Isophane ; Recombinant Proteins ; Area Under Curve ; Double-Blind Method ; Cross-Over Studies ; Therapeutic Equivalency
Chemical Substances	Insulin ; Insulin, Regular, Human ; Biosimilar Pharmaceuticals ; Hypoglycemic Agents ; Insulin, Isophane (53027-39-7) ; Recombinant Proteins
Language	English
Publishing date	2023-02-14
Publishing country	England
Document type	Randomized Controlled Trial ; Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1454944-x
ISSN	1463-1326 ; 1462-8902
ISSN (online)	1463-1326
ISSN	1462-8902
DOI	10.1111/dom.14994
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5442: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications

Loganathan, Subramanian / Athalye, Sandeep N. / Joshi, Shashank R.

Expert Opinion on Biological Therapy

2020 Volume 20, Issue 9, Page(s) 1025–1031

Keywords	Clinical Biochemistry ; Pharmacology ; Drug Discovery ; covid19
Language	English
Publisher	Informa UK Limited
Publishing country	uk
Document type	Article ; Online
ZDB-ID	2052501-1
ISSN	1471-2598
ISSN	1471-2598
DOI	10.1080/14712598.2020.1798399
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 6094: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin

Owen, Joel S / Rackley, Russell J / Hummel, Matthew A / Roepcke, Stefan / Huang, Hannah / Liu, Mark / Idris, Tazeen A / Murugesan, Sundara Moorthi Nainar / Marwah, Ashwani / Loganathan, Subramanian / Ranganna, Gopinath / Barve, Abhijit / Waller, Cornelius F / Socinski, Mark A

European journal of drug metabolism and pharmacokinetics

2023 Volume 48, Issue 6, Page(s) 675–689

Abstract: Background and objectives: MYL-1402O is a bevacizumab (Avastin: Methods: Efficacy and safety of MYL-1402O compared with EU-Avastin: Results: The pharmacokinetics of Avastin: Conclusions: PopPK analysis revealed no significant differences ... ...

Abstract	Background and objectives: MYL-1402O is a bevacizumab (Avastin Methods: Efficacy and safety of MYL-1402O compared with EU-Avastin Results: The pharmacokinetics of Avastin Conclusions: PopPK analysis revealed no significant differences between pharmacokinetics of MYL-1402O and Avastin
MeSH term(s)	Humans ; Bevacizumab/pharmacokinetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Biosimilar Pharmaceuticals/pharmacokinetics ; Lung Neoplasms/drug therapy ; Therapeutic Equivalency ; Double-Blind Method
Chemical Substances	Bevacizumab (2S9ZZM9Q9V) ; Biosimilar Pharmaceuticals
Language	English
Publishing date	2023-10-04
Publishing country	France
Document type	Randomized Controlled Trial ; Multicenter Study ; Journal Article
ZDB-ID	196729-0
ISSN	2107-0180 ; 0398-7639 ; 0378-7966
ISSN (online)	2107-0180
ISSN	0398-7639 ; 0378-7966
DOI	10.1007/s13318-023-00855-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1236: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study.

Lebovitz, Harold E / Fleming, Alexander / Cherrington, Alan D / Joshi, Shashank / Athalye, Sandeep N / Loganathan, Subramanian / Vishweswaramurthy, Ashwini / Panda, Jayanti / Marwah, Ashwani

Expert opinion on pharmacotherapy

2022 Volume 23, Issue 16, Page(s) 1855–1863

Abstract: Background: Efficacy and safety of ultra-rapid acting oral prandial insulin Tregopil was compared with insulin aspart (IAsp) in patients with type 2 diabetes (T2D) on insulin glargine and metformin.: Research design and methods: In this open-label, ... ...

Abstract	Background: Efficacy and safety of ultra-rapid acting oral prandial insulin Tregopil was compared with insulin aspart (IAsp) in patients with type 2 diabetes (T2D) on insulin glargine and metformin. Research design and methods: In this open-label, active-controlled trial, patients with T2D, HbA Results: The observed mean HbA Conclusions: Tregopil demonstrated an ultrafast, short-duration prandial profile with good safety. While Tregopil's early postprandial effects were comparable to IAsp, its late postprandial effects were inferior. Trial registration: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT03430856).
MeSH term(s)	Humans ; Diabetes Mellitus, Type 2/drug therapy ; Insulin/adverse effects ; Insulin/analogs & derivatives ; Insulin Aspart/adverse effects ; Insulin Glargine/adverse effects
Chemical Substances	Insulin ; Insulin Aspart (D933668QVX) ; Insulin Glargine (2ZM8CX04RZ)
Language	English
Publishing date	2022-11-09
Publishing country	England
Document type	Randomized Controlled Trial ; Clinical Trial, Phase II ; Clinical Trial, Phase III ; Journal Article
ZDB-ID	2001535-5
ISSN	1744-7666 ; 1465-6566
ISSN (online)	1744-7666
ISSN	1465-6566
DOI	10.1080/14656566.2022.2141569
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5130: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito